Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-11
2006-04-11
Balasurbramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S366000
Reexamination Certificate
active
07026322
ABSTRACT:
Methods of using a compound, its pharmaceutically acceptable salts, and/or its pro-drug esters, in isolated form, to treat cancer, and methods for isolating, for formulating, and for administering the compound, salt, and/or pro-drug ester as an antitumor agent, wherein the compound, salt, or pro-drug ester has the following structure:wherein:R1, R2, R5, R7, and R8are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24alkyl, unsaturated C1-C24alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,R3, R4, and R6are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12alkyl, unsaturated C1-C12alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,X1and X2are separately selected from the group consisting of an oxygen atom, and a sulfur atom, andthe dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond. Most preferably, R3and R4are hydrogen, and each are involved in hydrogen bonds, and/or the dashed bond is a double bond, such that the chemical backbone of the compound substantially retains a substantially planar conformation.
REFERENCES:
patent: 6069146 (2000-05-01), Fenical et al.
patent: 6358957 (2002-03-01), Fukumoto et al.
patent: 1 264 831 (2002-12-01), None
patent: 2143823 (1985-02-01), None
patent: 5009164 (1993-01-01), None
patent: 10130266 (1998-05-01), None
patent: WO 2004/054498 (2004-07-01), None
Ahmed, S.A. et al. “A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay.”J. Immunol. Methods.170, 211-224 (1994).
Algaier, J. et al. “The effects of dimethyl sulfoxide on the kinetics of tubulin assembly.”Biochim. Biophys. Acta.954, 235-43 (1988).
Ali M. et al. “Toxicity of echinulin fromAspergillus chevalieriin rabbits.”Toxicology Letters.48, 235-41 (1989).
Bond, R., et al., “The Synthesis of Viridamine, aPenicillium ViridicatumMycotoxin.”Synthetic Commun.19 (13&14), 2551-2566 (1989).
Borisy, G.G. “A Rapid Method for Quantitative Determination of Microtubule Protein using DEAE-Cellulose Filters.”Anal. Biochem.50, 373-385 (1972).
Cui, C. et al. “Novel Mammalian Cell Cycle Inhibitors, Tryprostatins A, B and Other Diketopiperazines Produced byAspergillus fumigatus.” J. Antibiotics.49, 534-40 (1996).
Cui, C. et al. “Novel Mammalian Cell Cycle Inhibitors, Tryprostatins A, B and Other Diketopiperazines ProducedAspergillus fumigatus.” J. Antibiotics.49, 527-33 (1996).
Goldani, L.Z. & Sugar, A.M. “Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug.”J. Antimicrob Chemother.33, 369-372 (1994).
Gordon, D., et al. “Reductive Alkylation on a Solid Phase: Synthesis of a Piperazinedione Combinatorial Library.”J. Bioorg. Med. Chem. Letters.5, 47-50 (1995).
Hamel, E. “Antimitotic Natural Products and Their Interactions with Tubulin.”Med. Res. Rev.16(2), 207-31 (1996).
Hartwell, L.H. et al. “Checkpoints: Controls that Ensure the Order of Cell Cycle Events.”Science.246, 629-34 (1989).
Horak R.M. et al. “Structure of the Austalides A-E, Five Novel Toxic Metabolites fromAspergillus ustus.” J.C.S. Chem. Comm.1265-67 (1981).
Iwasaki, S. “Bioactive Natural Products Interfering with Microtubule Function.”Kagaku to Seibutsu.32(3), 153-159 (1994).
Iwasaki, S. “Antimitotic Agents: Chemistry and Recognition of Tubulin Molecule.”Med Res Rev.13, 183-198 (1993).
Johnson, K.A. et al. “Kinetic Analysis of Microtubule Self-assembly in Vitro.”J. Mol. Biol.117, 1-31 (1977).
Keepers Y.P., et al., “Comparison of the Sulforhodamine B Protein and Tetrazolium (MIT) Assays for in vitro Chemosensitivity Testing.”Eur. J. Cancer.27, 897-900 (1991).
Kondoh, M. et al. “Effects of Tryprostatin Derivatives on Microtubule Assembly In Vitro and In Situ.”J. Antibiotics.51, 801-04 (1998).
Krishan, A. “Rapid Flow Cytofluorometric Analysis of Mammalian Cell Cycle By Propidium Iodide Staining.”J. Cell Biol.66, 188-193 (1975).
Kupchan, S.M. et al. “Steganacin and Steganangin, Novel Antileukemic Lignan Lactones fromSteganotaenia araliacea1-3.”J. Am. Chem. Soc.95(4), 1335-36 (1973).
Lacey, E. et al. “Interaction of Phomopsin A and Related Compounds with Purified Sheep Brain Tubulin.”Biochem. Pharmacol.36, 2133-38 (1987).
Laemmli, U.K. “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4.”Nature.227, 680-85 (1970).
Larsen, T.O et al. “Aurantiamine, A Kiketopiperazine from Two Varieties of Penicillium Aurantiogriseum.”Phytochemistry.31, 1613-1615 (1992).
Lee, J.C. et al. “The Reconstitution of Microtubules from Purified Calf Brain Tubulin.”Biochemistr.14(23), 5183-87 (1975).
Li, Y., et al. “Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding.”Chem. Biol. Interact.93, 175-83 (1994).
Liwo, A. et al. “Origin of the Ring-Ring Interaction in Cyclic Dipeptides Incorporating an Aromatic Amino Acid.”Tetrahedron Lett.26, 1873-1876 (1985).
Luduena, R.F. “Contrasting Roles of Tau and Microtubule-associated Protein 2 in the Vinblastine-induced Aggregation of Brain Tubulin.”J. Biol. Chem.259:12890-98 (1984).
Pettit, G.R. et al. “Antineoplastic Agents. 291. Isolation and Synthesis of Combretastatins A-4, A-5, and A-6 1a.”J. Med. Chem.38, 1666-1672 (1995).
Roberge, M. et al. “Antitumor Drug Fostriecin Inhibits the Mitotic Entry Checkpoint and Protein Phosphates 1 and 2A.”Cancer Res.54, 6115-21 (1994).
Rowinsky, E. K. et al. “Taxol: A Novel Investigational Antimicrotubule Agent.”J. Natl. Cancer Inst.82, 1247-59 (1990).
Sackett, D.L. “Podophyllotoxin, Steganacin and Combretastatin: Natural Products that Bind at the Colchicine Site of Tubulin.”Pharmacol. Ther.59, 163-228 (1993).
Sherline, P., et al. “Binding of Colchicine to Purified Microtubule Protein.”J. Biol. Chem.250, 5481-86 (1975).
Smedsgaard J. et al. “Using direct electrospray mass spectrometry in taxonomy and secondary metabolite profiling of crude fungal extracts.”J. Microbiol. Meth.25, 5-17 (1996).
Steyn, P.S. “The Structures of Five Diketopiperazines fromAspergillus Ustus.”Tetrahedron.29, 107-120 (1973).
Sugar, A., et al. “Comparison of Three Methods of Antifungal Susceptibility Testing with the Proposed NCCLS Standard Broth Macrodilution Assay: Lack of Effect of Phenol Red.”Diagn Micro and Infect Diseases.21, 129-133 (1995).
Takahashi, M., et al. “Rhizoxin binding to tubulin at the maytansine-binding site.”Biochim. Biophys. Acta.926, 215-23 (1987).
Tiwari, S.C. et al. “A pH- and Temperature-Dependent Cyclic Method that doubles the Yield of Microtubule Protein.”Anal. Biochem.215, 96-103 (1993).
Turner and Rodriguez. “Recent Advances in the Medicinal Chemistry of Antifungal Agents.”Current Pharmaceutical Design.2, 209-224 (1996).
Usui, T. et al. “Tryprostatin A, a specific and novel inhibitor of microtubule assembly.”Biochem J.333, 543-48 (1998).
Van der Waerden, B.L.Arch Exp Pathol Pharmakol.195, 389-412 (1940).
Verdier-Pinard, P., et al., “Structure-Activity Analysis of the Interaction of Curacin A, the Potent Colchicine Site Antimitotic Agent, with Tubulin and Effects of Analogs on the Growth of MCF-7 breast Cancer Cells.”Mol. Pharmacol.53, 62-76 (19
Grodberg Jennifer
Hayashi Yoshio
Palladino, Jr. Michael A.
Balasurbramanian Venkataraman
Knobbe Martens Olson & Bear LLP
Nereus Pharmaceuticals Inc.
LandOfFree
Phenylahistin and the phenylahistin analogs, a new class of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylahistin and the phenylahistin analogs, a new class of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylahistin and the phenylahistin analogs, a new class of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532879